Bibliographic details

Jansen JP, Gaugris S, Choy EH, Ostor A, Nash JT, Stam W.  Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDs in the treatment of ankylosing spondylitis. PharmacoEconomics 2010; 28(4): 323-344


This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.

CRD summary

Indexing status

Subject indexing assigned by NLM

Index terms

Anti-Inflammatory Agents, Non-Steroidal /economics /therapeutic use; Bayes Theorem; Cost-Benefit Analysis; Cyclooxygenase 2 Inhibitors /economics /therapeutic use; Diclofenac /economics /therapeutic use; Drug Costs; Drug-Related Side Effects and Adverse Reactions /economics; Great Britain; Humans; Markov Chains; Meta-Analysis as Topic; Models, Economic; Naproxen /economics /therapeutic use; Pyrazoles /economics /therapeutic use; Pyridines /economics /therapeutic use; Quality-Adjusted Life Years; Severity of Illness Index; Spondylitis, Ankylosing /drug therapy /economics; Sulfonamides /economics /therapeutic use; Sulfones /economics /therapeutic use; Treatment Outcome